Morteza Heidarzadeh

Morteza Heidarzadeh

Auto-generated profile, based on publicly available information

Morteza Heidarzadeh

Research Center for Translational Medicine, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2018 in Journal of Biological Engineering
Verified
Journal Article
Open access
PDF file
SSShirin Saberianpour
Shirin Saberianpour
MHMorteza Heidarzadeh
Morteza Heidarzadeh
MGMohammad Hossein Geranmayeh
Mohammad Hossein Geranmayeh
HHHossein Hosseinkhani
Hossein Hosseinkhani
RRReza Rahbarghazi
Reza Rahbarghazi
TNTannaz Novinbahador
Tannaz Novinbahador
Angiogenesis is touted as a fundamental procedure in the regeneration and restoration of different tissues. The induction of de novo blood vessels seems to be vital to yield a successful cell transplantation rate loaded on various scaffolds. Scaffolds are natural or artificial substances that are considered as one of the means for delivering, aligning, maintaining cell connection in a favor of angiogenesis. In addition to the potential role of distinct scaffold type on vascularization, the application of some strategies such as genetic manipulation, and conjugation of pro-angiogenic factors could intensify angiogenesis potential. In the current review, we focused on the status of numerous scaffolds applicable in the field of vascular biology. Also, different strategies and priming approaches useful for the induction of pro-angiogenic signaling pathways were highlighted.

18 February 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
MRMehdi Rahnavard
Mehdi Rahnavard
Mehdi HassanpourMehdi Hassanpour
Mehdi Hassanpour
MAMahdi Ahmadi
Mahdi Ahmadi
MHMorteza Heidarzadeh
Morteza Heidarzadeh
HAHassan Amini
Hassan Amini
NSNasser Safaie
Nasser Safaie

22 April 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
ESElhameh Shokrollahi
Elhameh Shokrollahi
ANAlireza Nourazarian
Alireza Nourazarian
RRReza Rahbarghazi
Reza Rahbarghazi
LSLeila Salimi
Leila Salimi
SKSaeede Karbasforush
Saeede Karbasforush
MHMorteza Heidarzadeh
Morteza Heidarzadeh

24 November 2020 in Journal of Cardiovascular and Thoracic Research
Verified
Journal Article
Open access
PDF file
Mehdi HassanpourMehdi Hassanpour
Mehdi Hassanpour
NANasser Aghamohamadzade
Nasser Aghamohamadzade
OCOmid Cheraghi
Omid Cheraghi
MHMorteza Heidarzadeh
Morteza Heidarzadeh
TNTannaz Novinbahador
Tannaz Novinbahador
Cardiovascular diseases (CVDs) are the leading cause of death globally. Because of the economic and social burden of acute myocardial infarction and its chronic consequences in surviving patients, understanding the pathophysiology of myocardial infarction injury is a major priority for cardiovascular research. MI is defined as cardiomyocytes death caused by an ischemic that resulted from the apoptosis, necrosis, necroptosis, and autophagy. The phases of normal repair following MI including inflammatory, proliferation, and maturation. Normal repair is slow and inefficient generally so that other treatments are required. Because of difficulties, outcomes, and backwashes of traditional therapies including coronary artery bypass grafting, balloon angioplasty, heart transplantation, and artificial heart operations, the novel strategy in the treatment of MI, cell therapy, was newly emerged. In cell therapy, a new population of cells has created that substitute with damaged cells. Different types of stem cell and progenitor cells have been shown to improve cardiac function through various mechanisms, including the formation of new myocytes, endothelial cells, and vascular smooth muscle cells. Bone marrow- and/or adipose tissue-derived mesenchymal stem cells, embryonic stem cells, autologous skeletal myoblasts, induced pluripotent stem cells, endothelial progenitor cells, cardiac progenitor cells and cardiac pericytes considered as a source for cell therapy. In this study, we focused on the point of view of the cell sources.